15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 14 firms covering 10X Genomics Inc, 5 rate it Buy or better, 9 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $19.00 to $70.00 (about 3.7x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $40.46 sits 35% below the current $62.64. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.00 next quarter toward $0.20 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 ratings
Moderate Buy
Strong Buy00%
Buy536%
Hold964%
Sell00%
Strong Sell00%
Based on 14 analysts giving stock ratings to 10X Genomics Inc.
As of Sep, 5 of 14 firms rate TXG a Buy (9 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TXG EPS & revenue forecast
EPS · NEXT QUARTER
$-0.00
Range $-0.06 – $0.05 · 3 analysts · -105% YoY
Next period, 3 analysts expect 10X Genomics Inc to earn $-0.00 a share (range $-0.06 – $0.05), versus $0.07 a year earlier. Full-year consensus is $0.10, growing to $0.20 the year after.
REVENUE · NEXT QUARTER
$171.9M
Range $169.0M – $177.2M · 3 analysts · +4% YoY
Revenue is expected to reach $171.9M (range $169.0M – $177.2M), +3.6% year-over-year. Full-year consensus is $620.4M, rising to $680.0M next year.
Top analysts covering 10X Genomics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TXG.
#1
David Westenberg
Piper Sandler · Rank #244
Hold
$47.00-25.0% to target
Overall win rate
33%
+ Follow
#2
Luke Sergott
Barclays · Rank #246
Buy
$52.00-17.0% to target
Overall win rate
40%
+ Follow
#3
KM
Kyle Mikson
Canaccord Genuity · Rank #263
Buy
$60.00-4.2% to target
Overall win rate
34%
+ Follow
#4
Patrick Donnelly
Citigroup · Rank #344
Hold
$50.00-20.2% to target
Overall win rate
30%
+ Follow
#5
CW
Casey Woodring
JP Morgan
Hold
$50.00-20.2% to target
Coverage
—
+ Follow
TXG stock forecast FAQ
What is TXG's average 12-month price target?+
The 13 analysts with a live target average $40.46 for 10X Genomics Inc over the next 12 months, ranging from a $70.00 high to a $19.00 low.
Is TXG stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 14 analyst ratings, 5 are Buy or Strong Buy, 9 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TXG?+
The Street-high target is $70.00 (RBC Capital), and the Street-low is $19.00 (TD Cowen). The average of all 13 active targets is $40.46.
How many Wall Street analysts cover TXG?+
14 analysts have an active rating on 10X Genomics Inc, and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering TXG?+
Among analysts who currently cover TXG, David Westenberg of Piper Sandler has the strongest overall Quantellect track record (Rank #244). Their current call is Hold with a $47.00 target.
What is 10X Genomics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.00 per share (range $-0.06 – $0.05) across 3 analysts. Full-year EPS is projected at $0.10, rising to $0.20 the following year.
How much revenue is 10X Genomics Inc expected to report next quarter?+
Consensus revenue is $171.9M (range $169.0M – $177.2M). Full-year revenue is projected at $620.4M, growing to $680.0M next year.
Have analysts been upgrading or downgrading TXG lately?+
As of Sep, 5 of 14 firms rate TXG a Buy (9 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TXG calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Citigroup
